Galena Biopharma (Nasdaq: GALE) announced the initiation of the Company's Institutional Review Board (IRB)-approved cancer patient registry study entitled RELIEF ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE